Scholarlink

<p>The selection of the best available donor is crucial for patients’ outcome after allogeneic stem cell transplantation (allo-SCT). In the absence of fully Human leucocyte antigen (HLA) -matched donors, mismatched unrelated donor (9/10-MUD) or haploidentical donor (haplo) can be considered. No consensus has been reached on the best alternative and large real-world data are warranted to support decisional processes. We compared the outcome of 1413 patients with myeloid malignancies undergoing allo-SCT from 9/10-MUD with anti-thymocyte-globulin (ATG) (<i>n</i> = 1134) or haplo with post-transplant cyclophosphamide (PT-Cy, <i>n</i> = 279) between 2009 and 2020 in 48 German centres. Donor type with related graft versus host disease (GvHD) prophylaxis showed in multivariable analysis no significant impact on acute GvHD development, both grade II-IV (HR 0.90, 95% CI 0.69–1.19, <i>p</i> = 0.469) and severe (HR 1.22, 95% CI 0.82-1.81, <i>p</i> = 0.319), nor on moderate to severe chronic GvHD (HR 0.78, 95% CI 0.59–1.03, <i>p</i> = 0.077). Moreover, no influence from donor type was observed on GVHD-relapse-free survival (HR 1.12, 95% CI 0.92–1.36, <i>p</i> = 0.227), progression-free survival (HR 1.2, 95% CI 0.95–1.51, <i>p</i> = 0.121), non-relapse mortality (HR 1.1, 95% CI 0.81–1.51, <i>p</i> = 0.542) and overall survival (HR 1.16, 95% CI 0.91–1.48, <i>p</i> = 0.235). Our real-world data demonstrate that haplo allo-SCT with PT-Cy is not inferior to 9/10-MUD allo-SCT with ATG.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Haploidentical transplantation with post-transplant cyclophosphamide is not inferior to 9/10-MUD transplantation with ATG in patients with myeloid malignancies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月8日

查看全文
  • Andrea Gantner,
  • Svenja Labuhn,
  • Daniel Fürst,
  • Sophie Mannes,
  • Sarah Flossdorf,
  • Francis Ayuketang Ayuk,
  • Thomas Schroeder,
  • Matthias Stelljes,
  • Robert Zeiser,
  • Peter Dreger,
  • Matthias Eder,
  • Igor Wolfgang Blau,
  • Johannes Schetelig,
  • Arne Brecht,
  • Andreas Burchert,
  • Matthias Edinger,
  • Verena Wais,
  • Hubert Schrezenmeier,
  • Hartmut Döhner,
  • Sandra Schmeller,
  • Katharina Fleischhauer,
  • Nicolaus Kröger,
  • Elisa Sala

摘要

The selection of the best available donor is crucial for patients’ outcome after allogeneic stem cell transplantation (allo-SCT). In the absence of fully Human leucocyte antigen (HLA) -matched donors, mismatched unrelated donor (9/10-MUD) or haploidentical donor (haplo) can be considered. No consensus has been reached on the best alternative and large real-world data are warranted to support decisional processes. We compared the outcome of 1413 patients with myeloid malignancies undergoing allo-SCT from 9/10-MUD with anti-thymocyte-globulin (ATG) (n = 1134) or haplo with post-transplant cyclophosphamide (PT-Cy, n = 279) between 2009 and 2020 in 48 German centres. Donor type with related graft versus host disease (GvHD) prophylaxis showed in multivariable analysis no significant impact on acute GvHD development, both grade II-IV (HR 0.90, 95% CI 0.69–1.19, p = 0.469) and severe (HR 1.22, 95% CI 0.82-1.81, p = 0.319), nor on moderate to severe chronic GvHD (HR 0.78, 95% CI 0.59–1.03, p = 0.077). Moreover, no influence from donor type was observed on GVHD-relapse-free survival (HR 1.12, 95% CI 0.92–1.36, p = 0.227), progression-free survival (HR 1.2, 95% CI 0.95–1.51, p = 0.121), non-relapse mortality (HR 1.1, 95% CI 0.81–1.51, p = 0.542) and overall survival (HR 1.16, 95% CI 0.91–1.48, p = 0.235). Our real-world data demonstrate that haplo allo-SCT with PT-Cy is not inferior to 9/10-MUD allo-SCT with ATG.